These data, in conjunction with decreased expression of immune-suppressive markers, PD-L1 and CD84, indicate in vivo OPN5 treatment functionally reverses the immune-suppressive activity and mechanisms of CLL-associated MDSCs. Here, OPN5 is linked to B-cell chronic lymphocytic leukemia.